A class action lawsuit has been filed against Embecta Corp. and certain senior executives for securities fraud related to statements about its insulin pen needle product category. The suit, pending in the U.S. District Court for the District of New Jersey, alleges that Embecta misled investors by touting the strength of its insulin pen portfolio while facing significant competition and overall market softness. On May 5, 2026, the company announced disappointing second-quarter results and a dividend cut from $0.15 to $0.01 per share, causing its stock to drop 57.8% from $9.25 to $3.90 per share. Investors have until August 17, 2026 to seek lead plaintiff appointment.
Embecta CorpSecurities fraud lawsuit alleges misrepresentations about insulin pen portfolio amid competition and market softness.